GM2 activator deficiency: An ultra-rare disorder with a new case and review of 22 published cases
- PMID: 40386041
- PMCID: PMC12083987
- DOI: 10.1016/j.ymgmr.2025.101225
GM2 activator deficiency: An ultra-rare disorder with a new case and review of 22 published cases
Abstract
GM2 activator deficiency (AB variant of GM2 gangliosidosis) is an ultra-rare autosomal recessive lysosomal storage disorder caused by pathogenic GM2A mutations. The loss of a functional GM2 activator protein disrupts GM2 ganglioside degradation, leading to progressive neurodegeneration. Although it shares clinical features with Tay-Sachs disease, GM2 activator deficiency remains a genetically and biochemically distinct disorder, with limited genotype-phenotype correlation due to the small number of reported cases. This report presents a 33-month-old male with an infantile-onset phenotype, characterized by nystagmus, axial hypotonia, hyperacusis, and bilateral cherry-red spots. Genetic analysis identified a homozygous likely pathogenic c.262_264del (p.Lys88del) mutation, reinforcing its potential association with early disease onset. His clinical course was marked by progressive neurodegeneration, recurrent pulmonary infections, and severe feeding difficulties requiring gastrostomy placement. In addition, previously published cases were reviewed to provide insights into the phenotypic spectrum, age of onset, and key clinical characteristics of GM2 activator deficiency. Among the 22 reported cases, 77.3 % exhibited an infantile-onset phenotype, while 18.2 % and 4.5 % had juvenile and adult-onset forms, respectively. Notably, cherry-red spots and hyperacusis were present in 94.1 % and 82.4 % of infantile cases but were strikingly absent in later-onset phenotypes. This case report, supplemented by a literature review, offers a comprehensive overview of GM2 activator deficiency and underscores the importance of early molecular diagnosis in suspected cases.
Keywords: AB variant GM2 gangliosidosis; Cherry-red spots; GM2 activator deficiency; GM2A.
© 2025 The Authors. Published by Elsevier Inc.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
GM2 gangliosidosis AB variant: novel mutation from India - a case report with a review.BMC Pediatr. 2016 Jul 11;16:88. doi: 10.1186/s12887-016-0626-6. BMC Pediatr. 2016. PMID: 27402091 Free PMC article. Review.
-
Two patients from Turkey with a novel variant in the GM2A gene and review of the literature.J Pediatr Endocrinol Metab. 2021 Apr 6;34(6):805-812. doi: 10.1515/jpem-2020-0655. Print 2021 Jun 25. J Pediatr Endocrinol Metab. 2021. PMID: 33819415 Review.
-
Atypical juvenile presentation of GM2 gangliosidosis AB in a patient compound-heterozygote for c.259G > T and c.164C > T mutations in the GM2A gene.Mol Genet Metab Rep. 2017 Apr 7;11:24-29. doi: 10.1016/j.ymgmr.2017.01.017. eCollection 2017 Jun. Mol Genet Metab Rep. 2017. PMID: 28417072 Free PMC article.
-
GM2 Activator Deficiency Caused by a Homozygous Exon 2 Deletion in GM2A.JIMD Rep. 2018;38:61-65. doi: 10.1007/8904_2017_31. Epub 2017 May 25. JIMD Rep. 2018. PMID: 28540636 Free PMC article.
-
Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8138-43. doi: 10.1073/pnas.94.15.8138. Proc Natl Acad Sci U S A. 1997. PMID: 9223328 Free PMC article.
References
-
- de Baecque C.M., Suzuki K., Rapin I., Johnson A.B., Whethers D.L. GM2-gangliosidosis, AB variant: clinico-pathological study of a case. Acta Neuropathol. 1975;33(3):207–226. - PubMed
-
- Wendeler M., Hoernschemeyer J., Hoffmann D., Kolter T., Schwarzmann G., Sandhoff K. Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation. Eur. J. Biochem. 2004;271(3):614–627. - PubMed
-
- Wendeler M., Werth N., Maier T., Schwarzmann G., Kolter T., Schoeniger M., et al. The enzyme-binding region of human GM2-activator protein. FEBS J. 2006;273(5):982–991. - PubMed
Publication types
LinkOut - more resources
Full Text Sources